Mendus

Att förändra hur cancer behandlasVi utforskar hur kraften i kroppens immunsystem kan användas för att förbättra långtidsöverlevnaden för cancerpatienter, samtidigt som hälsan och livskvaliteten bevaras.
Om oss
Intervju
<picture><source type="image/webp" srcSet="/static/011eed30522ead4243d8dc9c3853ff0f/17f30/Bertea-1-e1741255063224.webp 633w,/static/011eed30522ead4243d8dc9c3853ff0f/eec2e/Bertea-1-e1741255063224.webp 1265w,/static/011eed30522ead4243d8dc9c3853ff0f/f6d15/Bertea-1-e1741255063224.webp 2530w" sizes="(min-width: 2530px) 2530px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2530px) 2530px, 100vw" decoding="async" loading="lazy" src="/static/011eed30522ead4243d8dc9c3853ff0f/519b2/Bertea-1-e1741255063224.jpg" srcSet="/static/011eed30522ead4243d8dc9c3853ff0f/ba82e/Bertea-1-e1741255063224.jpg 633w,/static/011eed30522ead4243d8dc9c3853ff0f/536c3/Bertea-1-e1741255063224.jpg 1265w,/static/011eed30522ead4243d8dc9c3853ff0f/519b2/Bertea-1-e1741255063224.jpg 2530w" alt=""/></picture>
Leopold Bertea, CTOFem frågor till Leopold Bertea, Chief Technology Officer på MendusLäs intervjun
<picture><source type="image/webp" srcSet="/static/13d437486ac45d2df52b5e817f064fca/9287e/20250221-FPI-1-e1741254440674.webp 146w,/static/13d437486ac45d2df52b5e817f064fca/6c7c7/20250221-FPI-1-e1741254440674.webp 293w,/static/13d437486ac45d2df52b5e817f064fca/01f25/20250221-FPI-1-e1741254440674.webp 585w" sizes="(min-width: 585px) 585px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 585px) 585px, 100vw" decoding="async" loading="lazy" src="/static/13d437486ac45d2df52b5e817f064fca/7b422/20250221-FPI-1-e1741254440674.jpg" srcSet="/static/13d437486ac45d2df52b5e817f064fca/0c87a/20250221-FPI-1-e1741254440674.jpg 146w,/static/13d437486ac45d2df52b5e817f064fca/b532e/20250221-FPI-1-e1741254440674.jpg 293w,/static/13d437486ac45d2df52b5e817f064fca/7b422/20250221-FPI-1-e1741254440674.jpg 585w" alt=""/></picture>
Första patienten till AMLM22-CADENCE-studien Läs mer
<picture><source type="image/webp" srcSet="/static/c4c425d0ea81c7aa107d1a6819b95218/3b627/Q4-SWE-1-e1741254715532.webp 571w,/static/c4c425d0ea81c7aa107d1a6819b95218/8216d/Q4-SWE-1-e1741254715532.webp 1141w,/static/c4c425d0ea81c7aa107d1a6819b95218/15afc/Q4-SWE-1-e1741254715532.webp 2282w" sizes="(min-width: 2282px) 2282px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2282px) 2282px, 100vw" decoding="async" loading="lazy" src="/static/c4c425d0ea81c7aa107d1a6819b95218/6a1ce/Q4-SWE-1-e1741254715532.png" srcSet="/static/c4c425d0ea81c7aa107d1a6819b95218/67799/Q4-SWE-1-e1741254715532.png 571w,/static/c4c425d0ea81c7aa107d1a6819b95218/add54/Q4-SWE-1-e1741254715532.png 1141w,/static/c4c425d0ea81c7aa107d1a6819b95218/6a1ce/Q4-SWE-1-e1741254715532.png 2282w" alt=""/></picture>
Mendus publicerar bokslutskommuniké för 2024Läs mer
VD har ordet
<picture><source type="image/webp" srcSet="/static/f29e617994277fc1d28c9932d36064b7/e321d/manting-3-e1741254845907.webp 128w,/static/f29e617994277fc1d28c9932d36064b7/0841e/manting-3-e1741254845907.webp 256w,/static/f29e617994277fc1d28c9932d36064b7/cd676/manting-3-e1741254845907.webp 512w" sizes="(min-width: 512px) 512px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 512px) 512px, 100vw" decoding="async" loading="lazy" src="/static/f29e617994277fc1d28c9932d36064b7/f4d0d/manting-3-e1741254845907.jpg" srcSet="/static/f29e617994277fc1d28c9932d36064b7/b64ac/manting-3-e1741254845907.jpg 128w,/static/f29e617994277fc1d28c9932d36064b7/857d2/manting-3-e1741254845907.jpg 256w,/static/f29e617994277fc1d28c9932d36064b7/f4d0d/manting-3-e1741254845907.jpg 512w" alt=""/></picture>
Erik Manting, VDFörberedelserna för registreringsgrundande studier med vididencel i AML fortskrider enligt planLäs den senaste VD-kommentaren
<picture><source type="image/webp" srcSet="/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/b7e03/20250107-FDA-EMA-feedback-1-e1741256763283.webp 553w,/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/9cb32/20250107-FDA-EMA-feedback-1-e1741256763283.webp 1106w,/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/6415e/20250107-FDA-EMA-feedback-1-e1741256763283.webp 2212w" sizes="(min-width: 2212px) 2212px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2212px) 2212px, 100vw" decoding="async" loading="lazy" src="/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/b2e19/20250107-FDA-EMA-feedback-1-e1741256763283.png" srcSet="/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/c6558/20250107-FDA-EMA-feedback-1-e1741256763283.png 553w,/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/d4ea5/20250107-FDA-EMA-feedback-1-e1741256763283.png 1106w,/static/8d73314e81c05cc7e8ecba8d9d0fbf5c/b2e19/20250107-FDA-EMA-feedback-1-e1741256763283.png 2212w" alt=""/></picture>
Feedback från FDA och EMA stöder förberedelserna för registreringsgrundande studie med vididencelLäs mer
<picture><source type="image/webp" srcSet="/static/0ebad426d471866ce04c063cbfffef44/35b07/20241218-ALISON-topline-data-SWE-e1741256621857.webp 125w,/static/0ebad426d471866ce04c063cbfffef44/ef761/20241218-ALISON-topline-data-SWE-e1741256621857.webp 250w,/static/0ebad426d471866ce04c063cbfffef44/a76d4/20241218-ALISON-topline-data-SWE-e1741256621857.webp 500w" sizes="(min-width: 500px) 500px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 500px) 500px, 100vw" decoding="async" loading="lazy" src="/static/0ebad426d471866ce04c063cbfffef44/f13d4/20241218-ALISON-topline-data-SWE-e1741256621857.jpg" srcSet="/static/0ebad426d471866ce04c063cbfffef44/fd74d/20241218-ALISON-topline-data-SWE-e1741256621857.jpg 125w,/static/0ebad426d471866ce04c063cbfffef44/258f5/20241218-ALISON-topline-data-SWE-e1741256621857.jpg 250w,/static/0ebad426d471866ce04c063cbfffef44/f13d4/20241218-ALISON-topline-data-SWE-e1741256621857.jpg 500w" alt=""/></picture>
PressmeddelandeLäs mer
<picture><source type="image/webp" srcSet="/static/0c6adeaa4aebe4451f67afd2a00a1ec2/d5a02/20241209-ASH--e1741254362309.webp 622w,/static/0c6adeaa4aebe4451f67afd2a00a1ec2/46b30/20241209-ASH--e1741254362309.webp 1244w,/static/0c6adeaa4aebe4451f67afd2a00a1ec2/f8626/20241209-ASH--e1741254362309.webp 2487w" sizes="(min-width: 2487px) 2487px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2487px) 2487px, 100vw" decoding="async" loading="lazy" src="/static/0c6adeaa4aebe4451f67afd2a00a1ec2/36387/20241209-ASH--e1741254362309.jpg" srcSet="/static/0c6adeaa4aebe4451f67afd2a00a1ec2/62172/20241209-ASH--e1741254362309.jpg 622w,/static/0c6adeaa4aebe4451f67afd2a00a1ec2/e7c26/20241209-ASH--e1741254362309.jpg 1244w,/static/0c6adeaa4aebe4451f67afd2a00a1ec2/36387/20241209-ASH--e1741254362309.jpg 2487w" alt=""/></picture>
Mendus presenterar på ASH 2024Läs mer
Intervju
<picture><source type="image/webp" srcSet="/static/011eed30522ead4243d8dc9c3853ff0f/17f30/Bertea-1-e1741255063224.webp 633w,/static/011eed30522ead4243d8dc9c3853ff0f/eec2e/Bertea-1-e1741255063224.webp 1265w,/static/011eed30522ead4243d8dc9c3853ff0f/f6d15/Bertea-1-e1741255063224.webp 2530w" sizes="(min-width: 2530px) 2530px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2530px) 2530px, 100vw" decoding="async" loading="lazy" src="/static/011eed30522ead4243d8dc9c3853ff0f/519b2/Bertea-1-e1741255063224.jpg" srcSet="/static/011eed30522ead4243d8dc9c3853ff0f/ba82e/Bertea-1-e1741255063224.jpg 633w,/static/011eed30522ead4243d8dc9c3853ff0f/536c3/Bertea-1-e1741255063224.jpg 1265w,/static/011eed30522ead4243d8dc9c3853ff0f/519b2/Bertea-1-e1741255063224.jpg 2530w" alt=""/></picture>
Leopold Bertea, CTOFem frågor till Leopold Bertea, Chief Technology Officer på MendusLäs intervjun
<picture><source type="image/webp" srcSet="/static/13d437486ac45d2df52b5e817f064fca/9287e/20250221-FPI-1-e1741254440674.webp 146w,/static/13d437486ac45d2df52b5e817f064fca/6c7c7/20250221-FPI-1-e1741254440674.webp 293w,/static/13d437486ac45d2df52b5e817f064fca/01f25/20250221-FPI-1-e1741254440674.webp 585w" sizes="(min-width: 585px) 585px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 585px) 585px, 100vw" decoding="async" loading="lazy" src="/static/13d437486ac45d2df52b5e817f064fca/7b422/20250221-FPI-1-e1741254440674.jpg" srcSet="/static/13d437486ac45d2df52b5e817f064fca/0c87a/20250221-FPI-1-e1741254440674.jpg 146w,/static/13d437486ac45d2df52b5e817f064fca/b532e/20250221-FPI-1-e1741254440674.jpg 293w,/static/13d437486ac45d2df52b5e817f064fca/7b422/20250221-FPI-1-e1741254440674.jpg 585w" alt=""/></picture>
Första patienten till AMLM22-CADENCE-studien Läs mer

<picture><source type="image/webp" srcSet="/static/6353fde9b5d55b79a200688eba8a5f84/8cdf4/Startpage_1-1.webp 302w,/static/6353fde9b5d55b79a200688eba8a5f84/39272/Startpage_1-1.webp 603w,/static/6353fde9b5d55b79a200688eba8a5f84/0d01b/Startpage_1-1.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/6353fde9b5d55b79a200688eba8a5f84/e579d/Startpage_1-1.jpg" srcSet="/static/6353fde9b5d55b79a200688eba8a5f84/8f82e/Startpage_1-1.jpg 302w,/static/6353fde9b5d55b79a200688eba8a5f84/d2caf/Startpage_1-1.jpg 603w,/static/6353fde9b5d55b79a200688eba8a5f84/e579d/Startpage_1-1.jpg 1206w" alt="&lt;p&gt;Surfer woman running with surfboard in Lanzarote Canary Islands, Famara beach&lt;/p&gt;
"/></picture>
Att få övertagetIdag är återkommande tumörer den främsta orsaken till cancerrelaterade dödsfall. Vi strävar efter att minska tumöråterfall genom att utnyttja immunsystemet för att agera mot kvarvarande cancerceller.
Hur vi gör

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2-1.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2-1.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2-1.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2-1.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2-1.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
Nya sätt att göra skillnadVi tillämpar vår förståelse av dendritisk cellbiologi för att designa immunterapier mot cancer som stimulerar aktiv immunitet, den enda långvariga formen av immunitet.
Om oss

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3-1.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3-1.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3-1.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3-1.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3-1.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Investera i framtidens cancervårdMendus är noterat på NASDAQ Stockholm under tickersymbolen IMMU. Du hittar all relevant information om Mendus-aktien på vår investerarsida.
Investerare

Senaste nyheternaNyheter och Evenemang
Inga hittade artiklar

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/87758fef326f16eea4ca73895627c894/d3468/Startpage_5_mobile.jpg'); }

En livsförändrande karriärPå Mendus är vi starkt engagerade i att förbättra livet för människor med cancer. Och vi gör det som en grupp som värdesätter ärlighet och vi-känsla. Jobba hos oss och hjälp till att fundamentalt förändra cancerbehandling.  
Jobba hos oss